You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Myriad Genetics said this week a top-five insurer has issued a positive medical policy decision for the Prolaris prostate cancer test. Myriad, through a spokesman, declined to identify the insurer.
The updated guidelines confirm HER2 gene amplification assessed by ISH and protein overexpression assessed by IHC are primary predictors of responsiveness to HER2 therapy.
The list of regulated analytes needs to be reviewed and updated so that external quality controls are in place to protect patients, proficiency testing providers said.
An impetus for the review included the fact that companies are advertising and promoting liquid biopsy in areas where the technology has not yet proven its clinical utility.
These lobbying efforts aim to shore up willingness among legislators to step in and halt implementation of the NCD if certain provisions remain in the final version.
Exosome Diagnostics said this week that it has expanded the coverage of its ExoDx Prostate IntelliScore (EPI) cancer test to an additional 82 million covered lives in the US, bringing the total to about 100 million.
The similar analytic performance of LDTs and FDA-approved tests informs the ongoing debate about the regulation of in vitro testing.
The workgroup wanted to address the problem of variability in how bioinformatics pipelines are validated in order to improve the accuracy of NGS tests.
The registry, which has been approved by CMS, is designed to demonstrate quality pathology practices and maximize reimbursements.
Several commercial NIPT providers in the US said they are planning to participate in the new program.